Solid Biosciences Interest Expense 2011-2026 | SLDB

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Solid Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
652 K	1.1 M	-381 K	2 K	1 K	515 K	270 K	1 M	271 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.1 M	-381 K	381 K

Quarterly Interest Expense Solid Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
210 K	207 K	188 K	-	211 K	239 K	3 K	-	278 K	111 K	121 K	-	-13 K	-3 K	-10 K	-	-	3 K	-	-	-	1 K	1 K	-	56 K	77 K	212 K	-	38 K	118 K	31 K	-	228 K	504 K	176 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
504 K	-13 K	124 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.06	-0.93 %	$ 114 M	Canada
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	27.4 K	$ 0.55	-3.51 %	$ 9.61 M	China
Cumberland Pharmaceuticals CPIX	606 K	$ 4.58	-5.37 %	$ 64.4 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	47 K	$ 38.6	-27.96 %	$ 1.42 B	USA
Emergent BioSolutions EBS	87.9 M	$ 8.92	-0.78 %	$ 457 M	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Assertio Holdings ASRT	2.78 M	$ 11.9	1.06 %	$ 845 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Evolus EOLS	-539 K	$ 4.13	-3.73 %	$ 266 M	USA
Bausch Health Companies BHC	-28 M	$ 5.73	-3.7 %	$ 2.09 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Organogenesis Holdings ORGO	20 K	$ 2.87	-4.33 %	$ 378 M	USA
Perrigo Company plc PRGO	-13.2 M	$ 11.39	-7.89 %	$ 1.58 B	USA
Rockwell Medical RMTI	2.3 M	$ 0.9	-0.12 %	$ 21 M	USA
Sundial Growers SNDL	81 K	$ 1.53	0.66 %	$ 3.37 M	Canada
TherapeuticsMD TXMD	300 K	$ 2.22	-0.89 %	$ 23.2 M	USA
Veru VERU	862 K	$ 2.52	-3.82 %	$ 340 M	USA
Viatris VTRS	573 M	$ 14.89	-5.16 %	$ 17.9 B	USA
cbdMD YCBD	-29.5 K	$ 0.77	-4.37 %	$ 3.32 M	USA
Pacira BioSciences PCRX	-373 K	$ 22.1	3.85 %	$ 1.02 B	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.67	-3.51 %	$ 141 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.75	0.33 %	$ 35.9 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 2.75	-3.17 %	$ 3.41 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	46.6 M	$ 7.36	-3.16 %	$ 4.55 B	Canada
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA